We examined a question that hasnt received nearly enough attention: What are the cardiovascular consequences of stopping GLP-1 drugs? Al-Aly posted on LinkedIn
General inflammatory markers: High-sensitivity CRP (hs-CRP), the most responsive general marker Erythrocyte sedimentation rate (ESR) Fibrinogen Condition-specific markers: Rheumatoid arthritis: RF, anti-CCP, DAS28 score Hashimoto thyroiditis: TPO antibodies, thyroglobulin antibodies, TSH Psoriasis: PASI score, BSA involvement IBD: Fecal calprotectin, SES-CD or Mayo score Lupus: ANA, anti-dsDNA, complement C3/C4 Cytokine panels (when available): TNF-alpha IL-6 IL-1 beta IL-17 (particularly relevant for psoriasis and spondyloarthritis) The recommendation from most practitioners is baseline testing before starting, a 4 to 6 week interim check, and a full reassessment at 12 weeks
The role of GLP-1RAs in pain modulation, including IIH related headache, has also been explored (6)
(ii) altered muscle structure, as well as fat deposition within the soft tissues, can increase upper airway collapsibility